論文種別	原著(症例報告除く)
言語種別	英語
査読の有無	その他(不明)
表題	Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study).
掲載誌名	正式名：Cancer treatment and research communications 略　 称：Cancer Treat Res Commun ISSNコード：24682942/24682942
掲載区分	国外
巻・号・頁	pp.Online ahead of print
著者・共著者	Hidenobu Ishii, Koichi Azuma, Fumiaki Kiyomi, Kohei Yoshimine, Kazuki Uchida, Kazunori Tobino, Tadaaki Yamada, Tsutomu Iwasa, Hiroaki Kanemura, Toshiyuki Sumi, Eiji Iwama, Masataka Mori, Masaru Takenaka, Yuki Takeyasu, Takayasu Kurata, Shunsuke Misono, Kentaro Tanaka, Isamu Okamoto
発行年月	2025/09
概要	INTRODUCTION:Large cell neuroendocrine carcinoma (LCNEC) of the lung is a rare histologic type and is placed in the neuroendocrine tumor category along with small cell lung cancer (SCLC) at the latest histologic classification. Combination therapy with chemotherapy and immune checkpoint inhibitors is the standard of care for both non-small cell lung cancer and SCLC. However, the efficacy of immunochemotherapy for LCNEC has not yet been established.METHODS AND ANALYSIS:This prospective, multicenter, single-arm study will evaluate the efficacy of durvalumab plus carboplatin and etoposide in patients with advanced or relapsed LCNEC. Thirty patients were enrolled in this study. Patients will receive durvalumab intravenously combined with up to four cycles of carboplatin and etoposide, followed by durvalumab maintenance treatment. The primary endpoint is the objective response rate, and the key secondary endpoints are the duration of response, progression-free survival, overall survival, and safety.CONCLUSION:This is the prospective study to evaluate the efficacy of immunochemotherapy in patients with advanced or relapsed LCNEC. The results are expected to contribute to establishing the treatment strategy for LCNEC.
DOI	10.1016/j.ctarc.2025.101008
PMID	41037966